LIPID PROFILE PATTERNS AND ASSOCIATION BETWEEN GLYCATED HAEMOGLOBIN (HbA1C) AND ATHEROGENIC INDEX OF PLASMA (AIP) IN DIABETES PATIENTS AT A TERTIARY CARE HOSPITAL IN MALAYSIA
DOI:
https://doi.org/10.22159/ijpps.2017v9i6.18639Keywords:
API, Diabetes Mellitus, HbA1c, MalaysiaAbstract
Objective: There is lack of data regarding lipid patterns and the relationship of the atherogenic index of plasma (AIP with glycemic control in Malaysian diabetes patients. This study aimed to assess the lipid patterns and association of AIP with HbA1c in diabetes patients at a tertiary care hospital in Malaysia.
Methods: The study was conducted on 72 diabetes patients who were randomly chosen and agreed to participate in the study. AIP values were calculated using log triglycerides/high-density lipoprotein (TG/HDL) ratio. Data were analysed using SPSS 23.
Results: Mean age and body mass index (BMI) of the participants were 56.88±8.89 (years) and 28.81±4.78 (kg/m2) respectively. Hypercholesterolemia, hypertriglyceridemia, high low-density lipoprotein (LDL) values were found in 55.5 %, 41.7 %, 45.5 % of total participants respectively and less than desirable HDL values were observed in 25% of total participants. Overall, 37.5% patients were categorised into high-risk AIP category. BMI categories had a significant association with AIP category (p = 0.05). There was a significant positive correlation of AIP with HbA1c (r = 0.34; p = 0.0 04). HDL was negatively correlated with AIP (r = 0.27; p = 0.02). Duration of diabetes and ethnicity showed no significant association with AIP risk values.
Conclusion: Diabetes patients in this study exhibited significant lipid abnormalities with increased AIP. AIP was significantly correlated with HbA1c.
Downloads
References
Haffner SM, Association AD. Management of dyslipidemia in adults with diabetes. Diabetes Care 2003;26:S83.
Juutilainen A, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Type 2 diabetes as a Coronary Heart Disease Equivalent†an 18 y prospective population-based study in finnish subjects. Diabetes Care 2005;28:2901-7.
Expert Panel on Detection E. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486.
Taskinen MR. Diabetic dyslipidemia. Atheroscler Suppl 2002;3:47-51.
Masana L, Mangas A, Hernndez-Mijares A, Gonzlez-Santos P. Lipoprotein ratios: physiological significance and clinical usefulness in cardiovascular prevention. Vasc Health Risk Manage 2009;5:1033-42.
Dobiás̆ová M, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate inapoB-lipoprotein-depleted plasma (FER HDL). Clin Biochem 2001;34:583-8.
Dobiasova M. AIP-- an atherogenic index of plasma as a significant predictor of cardiovascular risk: from research to practice. Vnitrni Lekarstvi 2006;52:64-71.
Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004;141:421-31.
Selvin E, Steffes MW, Zhu H, Matsushita K, Wagenknecht L, Pankow J, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 2010;362:800-11.
World Health Organization WHO; 2011. Available from: http://www.who.int/nmh/countries/mys_en.pdf. [Last accessed on 07 Jun 2016]
Malaysia MoH. Ministry of Health Malaysia. Annual Report Putrajaya; 2010.
Butt M, Ali AM, Bakry MM, Mustafa N. Impact of a pharmacist led diabetes mellitus intervention on HbA1c, medication adherence and quality of life: a randomised controlled study. Saudi Pharm J 2016;24:40-8.
World Health Organization. Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus: abbreviated report of a WHO consultation. InUse of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus: abbreviated report of a WHO consultation; 2011.
Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: a meta-analysis of 37 prospective cohort studies. Br Med J 2006;332:73-8.
Wexler DJ, Grant RW, Meigs JB, Nathan DM, Cagliero E. Sex disparities in treatment of cardiac risk factors in patients with type 2 diabetes. Diabetes Care 2005;28:514-20.
Vinod Mahato R, Gyawali P, Raut PP, Regmi P, Singh KP, Raj Pandeya D, et al. Association between glycaemic control and serum lipid profile in type 2 diabetic patients: glycated haemoglobin as a dual biomarker. Biomed Res 2011;22:375-80.
Bittner V. Lipoprotein abnormalities related to women’s health. Am J Cardiol 2002;90:77-84.
Warren MP, Halpert S. Hormone replacement therapy: controversies, pros and cons. Best Pract Res Clin Endocrinol Metab 2004;18:317-32.
Dixit AK, Dey R, Suresh A, Chaudhuri S, Panda AK, Mitra A, et al. The prevalence of dyslipidemia in patients with diabetes mellitus of ayurveda Hospital. J Diabetes Metab Disord 2014;13:58.
Okpa HO, Enang OE, Effa EE, Essien OE, Mbu PN. Comparative analysis of the atherogenic index of plasma and its relationship with cardiovascular risk among patients with diabetes mellitus and concurrent diabetes mellitus with hypertension attending endocrinology clinic in a tertiary hospital South-South Nigeria. IOSR J Dental Med Sci 2015;14:102-7.
Otamere H, Aloamaka C, Okokhere P, Adisa W. Lipid profile in diabetes mellitus; what impact has age and duration. Br J Pharmacol Toxicol 2011;2:135-7.
Patel MB, Sachora WM, Pandya AR, Kothari AD, Patel JK. Can HbA1c Act as a surrogate marker for cardiovascular risk? IOSR J Dental Med Sci 2013;3:39-43.
Davis TM, Cull CA, Holman RR. The relationship between ethnicity and glycemic control, lipid profiles, and blood pressure during the first 9 Y of type 2 diabetes UK prospective diabetes study (UKPDS 55). Diabetes Care 2001;24:1167-74.
Zhang L, Qiao Q, Tuomilehto J, Janus ED, Lam TH, Ramachandran A, et al. Distinct ethnic differences in lipid profiles across glucose categories. J Clin Endocrinol Metab 2010;95:1793-801.
Blebil AQ, Hassan Y, Dujaili JA. Differences in demographics, lipid profile and other clinical characteristics among type 2 diabetic patients in the state of penang, Malaysia according to gender and races. Asian J Pharm Clin Res 2011;4 Suppl 2:130-3.
Samsudin IN, Md Saleh R, Chellappah Thambiah S, Hamzah MA, Syafira A, Khalik W, et al. Prevalence of dyslipidaemia in type 2 diabetes mellitus patients and its association to diabetic retinopathy in a Malaysian tertiary hospital. Malaysian J Med Health Sci 2014;10:47-51.
Chew BH, Ismail M, Lee PY, Taher SW, Haniff J, Mustapha FI, et al. Determinants of uncontrolled dyslipidaemia among adult type 2 diabetes in Malaysia: the Malaysian diabetes registry. Diabetes Res Clin Pract 2012;96:339-47.
Ismail IS, Nazaimoon W, Mohamad W, Letchuman R, Singaraveloo M, Hew F, et al. Ethnicity and glycemic control are major determinants of diabetic dyslipidaemia in Malaysia. Diabetic Med 2001;18:501-8.
Ozder A. Lipid profile abnormalities seen in T2DM patients in primary healthcare in Turkey: a cross-sectional study. Lipids Health Dis 2014;13:183.
Nansseu JRN, Moor VJA, Nouaga MED, Zing-Awona B, Tchanana G, Ketcha A. Atherogenic index of plasma and risk of cardiovascular disease among Cameroonian postmenopausal women. Lipids Health Dis 2016;15:41.
Niroumand S, Khajedaluee M, Khadem-Rezaiyan M, Abrishami M, Juya M, Khodaee G, et al. Atherogenic index of plasma (AIP): a marker of cardiovascular disease. Med J Islam Repub Iran 2015;29:240.
Konuru V, Sangam K, Mohammed A, Kanneganti S. Evaluation of pharmacoeconomic direct cost in diabetes patients. Asian J Pharm Clin Res 2017;10:38-40.
Published
How to Cite
Issue
Section
